Pylarify is a F 18-labeled, prostate-specific membrane antigen targeted PET agent used to pinpoint suspected metastasis or recurrence of the disease. 

Most nonhospital-based groups fall outside of the new CMS rule, but there’s still an opportunity to adopt this mindset and attract new customers, experts wrote recently. 

This is the FDA's second mammography warning in two days, with both centers going weeks without performing mandatory quality-control tests.

Rad involvement in these value-minded care-coordination efforts leapt threefold, preparing members of the specialty to take on downside risk while strengthening bonds with hospital partners.

CMS recently postponed the go-live date of the Medicare Coverage Innovative Technology rule for the second time.

The 32-page document covers everything from implanted devices to those fastened or carried by patients, such as external insulin pumps and pulse oximeters.

The final rule would eliminate lag time between the FDA approving new technology and the Centers for Medicare & Medicaid Services paying for it. 

Representatives recently introduced the Improving Seniors’ Timely Access to Care Act in the U.S. House, drawing support from the ACR, Medical Group Management Association and others.